157 related articles for article (PubMed ID: 11695547)
41. Oxymetholone: III. Evaluation in the p53+/- transgenic mouse model.
Stoll RE; Holden HE; Barthel CH; Blanchard KT
Toxicol Pathol; 1999; 27(5):513-8. PubMed ID: 10528630
[TBL] [Abstract][Full Text] [Related]
42. Xeroderma pigmentosum group A gene action as a protection factor against 4-nitroquinoline 1-oxide-induced tongue carcinogenesis.
Ide F; Oda H; Nakatsuru Y; Kusama K; Sakashita H; Tanaka K; Ishikawa T
Carcinogenesis; 2001 Apr; 22(4):567-72. PubMed ID: 11285190
[TBL] [Abstract][Full Text] [Related]
43. Committee on Carcinogenicity of Chemicals in Food, Consumer Products and theEnvironment. Statement on ILSI/HESI research programme on alternative cancer models.
Blain PG
Toxicol Pathol; 2003; 31(2):254-7. PubMed ID: 12696588
[No Abstract] [Full Text] [Related]
44. Combined oral benzo[a]pyrene and inhalatory ozone exposure have no effect on lung tumor development in DNA repair-deficient Xpa mice.
Hoogervorst EM; de Vries A; Beems RB; van Oostrom CT; Wester PW; Vos JG; Bruins W; Roodbergen M; Cassee FR; Vijg J; van Schooten FJ; van Steeg H
Carcinogenesis; 2003 Mar; 24(3):613-9. PubMed ID: 12663525
[TBL] [Abstract][Full Text] [Related]
45. Benzo[a]pyrene (BP) DNA adduct formation in DNA repair-deficient p53 haploinsufficient [Xpa(-/-)p53(+/-)] and wild-type mice fed BP and BP plus chlorophyllin for 28 days.
John K; Pratt MM; Beland FA; Churchwell MI; McMullen G; Olivero OA; Pogribny IP; Poirier MC
Carcinogenesis; 2012 Nov; 33(11):2236-41. PubMed ID: 22828138
[TBL] [Abstract][Full Text] [Related]
46. Assessment of human cancer risk: challenges for alternative approaches.
Omenn GS
Toxicol Pathol; 2001; 29 Suppl():5-12. PubMed ID: 11695561
[TBL] [Abstract][Full Text] [Related]
47. Differential ultraviolet-B-induced immunomodulation in XPA, XPC, and CSB DNA repair-deficient mice.
Boonstra A; van Oudenaren A; Baert M; van Steeg H; Leenen PJ; van der Horst GT; Hoeijmakers JH; Savelkoul HF; Garssen J
J Invest Dermatol; 2001 Jul; 117(1):141-6. PubMed ID: 11442761
[TBL] [Abstract][Full Text] [Related]
48. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI.
MacDonald J; French JE; Gerson RJ; Goodman J; Inoue T; Jacobs A; Kasper P; Keller D; Lavin A; Long G; McCullough B; Sistare FD; Storer R; van der Laan JW
Toxicol Sci; 2004 Feb; 77(2):188-94. PubMed ID: 14657512
[TBL] [Abstract][Full Text] [Related]
49. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment.
Gulezian D; Jacobson-Kram D; McCullough CB; Olson H; Recio L; Robinson D; Storer R; Tennant R; Ward JM; Neumann DA
Toxicol Pathol; 2000; 28(3):482-99. PubMed ID: 10862569
[TBL] [Abstract][Full Text] [Related]
50. Criteria for the evaluation of studies in transgenic models.
Popp JA
Toxicol Pathol; 2001; 29 Suppl():20-3. PubMed ID: 11695558
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of the carcinogenic potential of clofibrate in the p53+/- mouse.
Torrey CE; Campbell JA; Hoivik DJ; Miller RT; Allen JS; Mann PC; Selinger K; Rickert D; Savina PM; Santostefano MJ
Int J Toxicol; 2005; 24(5):289-99. PubMed ID: 16257849
[TBL] [Abstract][Full Text] [Related]
52. Studies of in vivo mutations in rpsL transgene in UVB-irradiated epidermis of XPA-deficient mice.
Murai H; Takeuchi S; Nakatsu Y; Ichikawa M; Yoshino M; Gondo Y; Katsuki M; Tanaka K
Mutat Res; 2000 May; 450(1-2):181-92. PubMed ID: 10838142
[TBL] [Abstract][Full Text] [Related]
53. Transgenic and knockout mice for DNA repair functions in carcinogenesis and mutagenesis.
Wijnhoven SW; van Steeg H
Toxicology; 2003 Nov; 193(1-2):171-87. PubMed ID: 14599776
[TBL] [Abstract][Full Text] [Related]
54. Genetically altered mouse models for identifying carcinogens.
Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
[No Abstract] [Full Text] [Related]
55. Toxicity and carcinogenicity studies of chlorpromazine hydrochloride and p-cresidine in the p53 heterozygous mouse model.
Petruska JM; Frank DW; Freeman GB; Evans EW; MacDonald JS
Toxicol Pathol; 2002; 30(6):696-704. PubMed ID: 12512871
[TBL] [Abstract][Full Text] [Related]
56. Early p53-positive foci as indicators of tumor risk in ultraviolet-exposed hairless mice: kinetics of induction, effects of DNA repair deficiency, and p53 heterozygosity.
Rebel H; Mosnier LO; Berg RJ; Westerman-de Vries A; van Steeg H; van Kranen HJ; de Gruijl FR
Cancer Res; 2001 Feb; 61(3):977-83. PubMed ID: 11221893
[TBL] [Abstract][Full Text] [Related]
57. Heterozygous p53-deficient mice are not susceptible to 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) carcinogenicity.
Park CB; Kim DJ; Uehara N; Takasuka N; Hiroyasu BT; Tsuda H
Cancer Lett; 1999 May; 139(2):177-82. PubMed ID: 10395176
[TBL] [Abstract][Full Text] [Related]
58. Role of nucleotide excision repair and p53 in zidovudine (AZT)-induced centrosomal deregulation.
Momot D; Nostrand TA; John K; Ward Y; Steinberg SM; Liewehr DJ; Poirier MC; Olivero OA
Environ Mol Mutagen; 2014 Dec; 55(9):719-26. PubMed ID: 25073973
[TBL] [Abstract][Full Text] [Related]
59. Highlights of International meeting on Alternative Methods of Carcinogenicity Testing, Leesburg, VA, November 1-3, 2000, Sponsored by the Health and Environmental Sciences Institute.
Jollow DJ
J Agromedicine; 2004; 9(2):427-9. PubMed ID: 19785235
[No Abstract] [Full Text] [Related]
60. Evaluation on carcinogenicity of chemicals using transgenic mice.
Mitsumori K
Toxicology; 2002 Dec; 181-182():241-4. PubMed ID: 12505318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
